Kauliv (Teriparatide)

Teriparatide is a synthetic fragment of human parathyroid hormone. After subcutaneous injection it binds to the PTH1 receptor on bone‑forming cells (osteoblasts), activating signaling pathways that increase osteoblast activity, improve calcium absorption, and promote the synthesis of new bone tissue.

The exact dose and treatment schedule are determined by the prescribing clinician based on the patient’s condition, age, renal function, and calcium status. In clinical practice teriparatide is often given as a daily subcutaneous injection, but the prescriber sets the precise regimen.

Safety data for teriparatide during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Kauliv product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Kauliv (teriparatide) is an anabolic therapy that builds new bone, whereas bisphosphonates and denosumab are anti‑resorptive agents that slow bone breakdown. In patients with severe osteoporosis or those who have failed anti‑resorptive therapy, teriparatide can provide greater gains in bone density and fracture risk reduction, but it is typically limited to a defined treatment period.

Kauliv must be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If the temperature rises above the recommended range, discard the product in accordance with local regulations.

Kauliv is given by subcutaneous injection, usually into the thigh or abdomen. The injection site should be rotated with each dose to minimize local irritation. Patients or caregivers should be trained on proper aseptic technique, needle handling, and disposal of used syringes according to local safety guidelines.

The most serious adverse events associated with teriparatide include hypercalcemia (elevated blood calcium), the rare possibility of osteosarcoma (observed in animal studies), and severe hypotension immediately after injection. Patients should be monitored for symptoms such as excessive thirst, muscle weakness, unexplained pain, or a sudden drop in blood pressure.

Kauliv is contraindicated in individuals with known hypersensitivity to teriparatide or any component of the formulation, patients with active bone malignancies, those who have received radiation therapy to the skeleton, and persons with unexplained hypercalcemia. Caution is also advised for patients with severe renal impairment.